SUBJECT INDEX

A

Acanthosis nigricans, 199, 202, 373–78
  treatment of, 378
Acquired immunodeficiency syndrome (AIDS), 69–82, 179–83, 221, 253–56, 287–93, 391–400, 403
  allergic interstitial nephritis and, 395
  antiviral drug resistance and, 253–56
  child abuse and, 221
  cytomegalovirus infection and, 180
  diarrheagenic infections and, 403
  herpes virus and, 253–56
  nephropathy and, 391–400
  pneumonitis infection and, 287–93
  renal disease and, 391–400
  see also AIDS
Acute myeloid leukemia
  cell differentiation and, 381, 385–86
  hematopoietic growth factors and, 381, 385
  immunophenotyping for, 381, 384, 387
  retinoic acid and, 385–87
Acyclovir, 179, 181, 185, 248–56
  viral resistance to, 250–56
Adenine nucleotide pool
  anaerobic glycosis and, 225–26, 230–32
Adenosine triphosphate
  regulation of cytosolic Ca^{2+} and, 418–27
Adrenocorticotropic hormone (ACTH)
  affective disorders and, 519–30
Advanced glycosylation end products (AGEPs), 159–65
  irreversible accumulation of, 160–61
  pathologic consequences of, 161–64
Affective disorders, 151–57, 261–65, 519–30
  basal ganglia lesions and, 261–65
  genetic epidemiology of, 152–54
  hypothalamic-pituitary-adrenocortical (HPA) axis and, 519–30
  leukoencephalopathy and, 261–65
  linkage studies in, 152–54
  log of odds (LOD) scores in, 152–54
AIDS Clinical Treatment Groups (ACTG), 73–74
AIDS-related complex (ARC)
  AZT resistance and, 75
Airway hyperresponsiveness, 139–48
  asthma and, 139–48
  mechanisms for, 142–45
Alcohol withdrawal syndrome, 323–37
  assessment of, 325–26
  comorbidity, 325, 335–37
  complications of, 325, 33–35
  pharmacology for, 326–33
Alcoholism
  hypercortisolism and, 528
Allergic interstitial nephritis (AIN), 395
Alzheimers disease, 528–29
Amantadine, 248–49
Aminoguanidine
  advanced glycosylation product inhibition and, 159, 164–65
Anabolic-androgenic steroid hormones
  see Androgens
Anaerobic glycolysis, 225, 228–32, 236, 427
  adenine nucleotide pool and, 225–26, 230–32
Androgens, 199–204, 449–54
  behavioral effects of, 453
  cardiovascular disease risk and, 453
  diabetes and, 199–204
  liver tumors and, 453–54
  polycystic ovarian disease and, 199–204
Anemia
  megaloblastic, 311–20
Angina
  accelerated, 36, 39–40
  unstable, 4, 35–37, 40–44
    stunned myocardium and, 4
Angioplasty
  hibernating myocardium and, 1, 5–6
  ischemia and, 228
Angioscopy, 35–36
Anorexia, 205, 214
  corticotropin releasing factor and, 214
Anticoagulation therapy, 511–12
Antihypertensives, 533–44
Antineutrophil cytoplasmic autoantibodies, 460–67
Antiviral chemotherapy, 179–85
Antiviral drug resistance, 247–57
  AIDS and, 253–56
  herpesvirus and, 247–57
  molecular basis of, 248–50
Anxiety disorder, 528
Apolipoproteins, 357–67
  coronary heart disease susceptibility and, 357–67
Arrhythmias
  cocaine abuse and, 133, 136–37
Aspergillosis, 480–82
Asthma
  airway hyperresponsiveness and, 139–48
    mechanism for, 142–45
Atheroma
  stable, 37–38
  ulcerated, 35
Atherosclerosis
  lipoprotein transport gene abnormalities and, 357–67
Autoimmune disease, 459–67
Autoimmunity, 91–95, 189–95
  bone marrow transplantation and, 189–95
  Hashimoto's thyroiditis and, 91–95
AZT
  see Zidovudine

B

Basal ganglia
  affective disorders and, 261–65
Battering
  child
  see Child abuse
Benign prostatic hypertrophy (BPH), 10
Benzodiazepines
  treatment for alcohol withdrawal syndrome and, 331–32, 336–37
Beta blockers
  treatment for alcohol withdrawal syndrome and, 331–32
Bipolar illness, 151–57
Blood pressure
  diet and, 347–53
  electrolytes and, 347–53
Bone cell metabolism, 17–23

Bone disease
metabolic, 17
Bone formation, 17–23
Bone marrow disease
megaloblastic anemia and, 311–20
Bone marrow transplantation, 189–95
graft-versus-host disease and, 189–95
chronic, 194–95
herpesvirus and, 191
histocompatibility and, 190
T-lymphocyte depletion and, 191–92
immunocompetence and, 195
Bone mineral density
thyroid hormone and, 341–45
Bone modeling, 17–23
Bone morphogenetic proteins, 22

C

Cachexia
cancer, 205, 214
Calcium
blood pressure and, 350–52
hypertrophy and, 429–30
myocardial relaxation and, 418–32
Calcium homeostasis
abnormalities in
myocardial stunning and, 3
Calciuresis
hypertension and, 350–51
Cancer
multidrug resistance and treatment of, 277–85
prostate, 9–15
diagnosis of, 10–12
prostate-specific antigen and, 9–15
radical prostatectomy and, 9
staging of, 12–13
treatment of, 13–15
see also Prostate cancer
Carbamazepine
treatment for alcohol withdrawal syndrome and, 330
Cardiomyopathy
cocaine abuse and, 135–36
Cardiopulmonary bypass
myocardial stunning and, 4
Cell activation, 567, 568–79
Chemotaxis, 567, 569
Chemotherapy
multidrug resistance and, 277–85
Chemotherapy
human immunodeficiency virus and, 69–82
Child abuse, 217–24
AIDS and, 221
eating disorders and, 221
epidemiology of, 218
mental retardation from, 220
Child abusers
physician's legal responsibilities and, 223
Children
diarrheagenic infections among, 403–8
Chloride
blood pressure and, 347–53
Chronic myelogenous leukemia (CML), 169
Chronic pulmonary embolism, 507–16
anticoagulation therapy and, 511–12
embolectomy and, 507–16
Clindamycin, 287, 289
Clonal origin, 167
Clonality
acquired hematologic disorders and, 491–502
Clonidine
treatment for alcohol withdrawal syndrome and, 331
Cobalamin, 311–20
deficiency of
megaloblastic anemia and, 311–20
Schilling test for, 318–19
Cocaine abuse
arrhythmias and, 133, 136–37
cardiomyopathy and, 135–36
myocardial infarction and, 133–35
myocarditis and, 133, 135–36
spasm and, 133–35
Common acute lymphoblastic leukemia antigen (CALLA), 169
Congestive heart failure
diastolic dysfunction and, 411–32
Coronary angioplasty, 47–56
angiographic outcome of, 51
clinical outcome of, 48–51
follow-up, 47
late results, 47
outcome compared to bypass surgery, 55–56
percutaneous transluminal, 47
Coronary artery disease, 119–25
echocardiography and, 119, 122
exercise stress testing and, 119–20
nonexercise testing and, 122–25
nuclear cardiology and, 119–25
thallium scintigraphy and, 119–25
Coronary artery disease, 127–32
Coronary balloon dilation, 47–56
see Coronary angioplasty
Coronary disease
graft
see Graft coronary disease
Coronary thrombosis, 35–44
Corticosteroids
Pneumocystis carinii pneumonitis and, 287
Corticotropin-releasing hormone (CRH), 519–30
Cryoglobulinemia
mixed, 460
Cushing's syndrome, 525
pseudo-, 528
Cytogenetics
acute myeloid leukemia and, 381–84, 387
Cytokines, 17–23, 25, 29, 567–79
bone cell metabolism and, 17–23
glomerular function and, 25, 29
wound repair and, 567–79
Cytomegalovirus, 61, 65–66, 179–85, 247–56, 303
transfusion-associated, 303
Cytomegalovirus (CMV) infection, 179–85
prevention of, 183
treatment of
acyclovir and, 179, 181
foscarnet and, 179, 182–83, 185
ganciclovir and, 179, 181–82, 185

D

Dapasone, 292–93
Depression
see Affective disorders
Dexamethasone suppression test, 524
Diabetes mellitus, 159–65, 373–75, 353–44
advanced glycosylation end products and, 159–65
aminoguanidine and, 164–65
hypertension and, 533–44
insulin-dependent, 373, 533
non-insulin-dependent, 373–75, 533
Diabetic hypertension, 533–44

Dialysis
restenosis and, 131
Diarrhea
bacterial, 404–6
infectious, 403–8
AIDS and, 403
children and, 403
mechanisms of, 403–4
parasitic, 406–8
secretory, 404
Diastolic dysfunction
congestive heart failure and, 411–32
Dideoxycytosine, 76–77
Dideoxyinosine, 77–78
Diet
hypertension and, 347–53
Differentiation, 381, 385–86
acute myeloid leukemia cells and, 385–86
Difluoromethylornithine (DFMO), 287, 289
Digital rectal examination, 10, 12
DNA
advanced glycosylation end products and, 159–65
Doppler echocardiography, 423
Doxorubican, 277–78
Drug resistance
multi-
cancer treatment and, 277–85
Drug testing
androgenic hormones and, 455–56

E

Eating disorders
childhood maltreatment and, 221
hypothalamic-pituitary-adrenocortical (HPA) axis and, 519–30
Echocardiography, 119, 122
Elderly
organic depression in, 261–65
leukoencephalopathy and, 261–65
tuberculosis among, 267–75
Embolectomy, 507–16
technique, 513–14
Enteral feeding, 553–54
Enteritis, 403–6
bacterial, 403–6
E. coli and, 404–5
enterotoxigenic
children and, 404–5
Enterotoxin, 403–5
diarrheagenic infection and, 403–5
Epstein-Barr virus, 61, 64–65
Escherichia coli, 403–5
bacterial enteritis and, 404–5
Exercise stress testing, 119–22
Extracellular matrix
glycosylation and, 159–65

F

Fabry's disease, 418
Fansidar, 287, 289, 293
Fibrosis
cardiac transplantation and, 444–45
Folate, 311–14
deficiency of
megaloblastic anemia and, 311–20
Foscarnet, 179, 182–83, 185, 248, 251

G

Gamma amino butyric acid (GABA)
regulation of food intake and, 210
Ganciclovir, 179, 181–82, 185, 248, 251
viral resistance to, 251
Gene therapy, 277–85
Genetics
lipoprotein transport proteins and, 357–67
Genome, 61
Giardia lamblia, 406–7
Glomerulonephritis, 25–31, 459–67
cell-mediated immunity in, 25–31
human, 27–31
rapidly progressive, 27–28
Glomerulosclerosis, 29–30, 391, 398–99
focal and segmental, 391, 398–99
Glucocorticoid, 519
Glycosylation, 159–65
Glycosylation inhibitors, 164–65
Goodpasture's syndrome, 460
Graft coronary disease, 437, 442–43, 445–46
long-time survivors and, 445–46
Graft-versus-host disease, 189–95
age-dependent incidence of, 190–93
chronic, 194–95
histocompatibility and, 190
phrophylaxis, 192–93
Growth factors, 17–23, 159–65, 567–79
bone cell metabolism and, 17–23
glycosylation and, 159–65
wound repair and, 567–79
Gynecomastia
androgenic hormone use and, 449, 452–53

H

HAIR-AN syndrome, 199, 201–3
linkage analysis and, 202
Hashimoto's thyroiditis
autoimmune basis for, 91–95
Hematologic disorders
acquired, 491–502
Hematopoiesis, 23
Hematopoietic growth factors, 381, 385
acute myeloid leukemia and, 381, 385
Hemodialysis
HIV infection and, 393
Hemostasis, 297–98, 304
Henoch-Schönlein purpura, 460
Hepatitis
transfusion-associated, 302–3
Herpes simplex virus, 61–64, 247–57
types 1 and 2, 61–64
Herpesviruses, 61–66, 191, 247–57
graft-versus-host disease and, 191
herpes simplex virus, 61–64, 247–57
human, 61–66
latency of, 61–66
number 6 (HHV6), 61, 66
resistance to acyclovir and, 250–53
High-density lipoprotein
coronary heart disease risk and, 358, 363–65
Hodgkin's disease, 502
Homocysteine, 311, 316–20
cobalamin deficiency and, 311, 316–20
Hormonal therapy, 9–10, 14–15
Human herpes virus no. 6 (HHV6), 61, 66
Human immunodeficiency virus (HIV), 69–82, 301–2, 391–400
chemotherapy for
dideoxycytosine, 76–77
dideoxyinosine, 77–78
glycosylation inhibitors and, 80
hypericin, 81
immunomodulating compounds and, 82

interferon, 81–82
nonnucleoside reverse transcriptase inhibitors and, 79–80
protease inhibitors and, 80
tat inhibitors and, 80
zidovudine (AZT), 69–76, 82
nephropathy and, 391–400
nephrotic syndrome and, 391–400
transfusion-associated, 301–2
Human immunodeficiency virus associated nephropathy (HIVAN), 391–400
zidovudine (AZT) and, 399–400
Human T-lymphocytotropic virus (HTLV)
modes of transmission of, 99–100
multiple sclerosis and, 102
polymerase chain reaction and, 99
type I, 97–103
type II, 97–103
Human T-lymphocytotropic virus I related myelopathy, 97
Hyperandrogenism, 199–204, 373–78
hyperinsulinemia and, 200–4
treatment of, 377–78
Hypercortisolism, 522–30
Hyperglycemia, 159–65
diabetic tissue damage and, 159–60
Hypericin, 81
Hyperinsulinemia
hyperandrogenism and, 200–4
polycystic ovarian disease and, 199–201
Hypertension, 347–53, 508, 514, 533–44
calciuresis and, 350–51
diabetic, 533–44
sodium and, 537
diabetic nephropathy and, 535
pulmonary, 508, 514
Hyperthyroidism
bone mineral density and, 341–45
Hypertrophy, 411, 417, 428–30, 443–45
cardiac transplantation and, 443–45
impaired calcium handling and, 428–30
Hypothalamic-pituitary-adrenocortical (HPA) axis
affective disorders and, 519–30
Hypothyroidism, 91–95

I

Immediate-early genes, 61–62
Immunity
cell-mediated
glomerulonephritis and, 25–31
Immunocompromised host, 287–93
Immunoglobulin immunoprophylaxis, 179, 184–85
Immunomodulating compounds, 82
Immunophenotyping
leukemia and, 381, 384, 387
Immunoprophylaxis
immunoglobulin, 179, 184–85
Immunosuppression
cardiac transplantation and, 437, 440–42
Immunotherapy, 179, 185
Infection
opportunistic
cardiac transplantation and, 437, 440
Infections
diarrheagenic, 403–8
AIDS and, 403
children and, 403
mechanisms of, 403
Inflammation
lung function and, 139–48
platelet-dervived growth factor and, 567–79
Injury
heart
irreversible, 225, 236–40
reversible, 225, 236–40
Insulin-like growth factors
bone metabolism and, 20–21
Insulin receptor gene, 199–203
polycystic ovarian disease and, 199–203
Insulin receptors, 373, 376–77
Insulin resistance, 199–204, 373–77, 533, 538–41
polycystic ovarian disease and, 199–204, 374
acanthosis nigricans and, 373–78
diabetes mellitus and, 373–75
hyperandrogenism and, 373–78
Interferon, 81–82, 174–75
plasma cell myeloma and, 174–75
tumor progression and, 174–75
Intestinal ischemia
mesenteric
acute, 107–17
nonocclusive, 107–17
Intestine
diarrheagenic infections of, 403–8
Intimal hyperplasia, 127, 129–30
Ion gradients
myocardial ischemia and, 225, 234–35
Ischemia
acute, 425–28
acute myocardial, 225–40
intestinal, 107–17
myocardial, 119–25
regional, 426
see also Myocardial ischemia

L

Left ventricle
diastolic dysfunction and, 411–32
diastolic pressure-volume relation and, 411
Lethal perfusion injury, 225, 236–37
Leukemia
acute, 495, 499–500
acute myeloid, 381–87
hematopoietic growth factors and, 381, 385
immunophenotyping for, 384
retinoic acid and, 385–87
adult T-cell, 97–98, 100–1
bone marrow transplantation and, 189–95
chronic lymphocytic, 501
chronic myelocytic, 495–96
transfusions and, 299–300
refractoriness and, 299
Leukocytoclastic angiitis, 460
Leukoencephalopathy, 261–65
organic depression and, 262
Linkage
affective disorders and, 151–54
schizophrenia and, 155–56
Lipoprotein
high-density, 358, 363–65
low-density, 358–62
very-low-density, 358, 363–65
Lipoprotein-associated antigen, 365–66
Lipoprotein lipase (LPL), 357–58, 364–65
Loffler's endocarditis, 418
Log of odds (LOD) scores
linkage studies in affective disorders and, 151–56

Low-density lipoprotein (LDL)
coronary heart disease risk and, 358–62
Lymphocytes, 25–31
glomerular dysfunction and, 25–31
Lymphoma, 491–92, 500–2
Hodgkin's disease, 502
Low-flow syndrome, 107
Lung function
airway hyperresponsiveness and, 139–48
inflammation and, 139–48
Lupus, 459–60
Lytic pathogens, 61–66

M

Macrophages
glomerular dysfunction and, 25, 28–30
glomerulosclerosis and, 29–30
proteinuria and, 28–29, 31
ulcerated atheroma and, 35
Magnesium
blood pressure and, 347, 351–52
Major depressive disorder, 151–54
linkage studies in, 152–54
Malnutrition, 549–63
Mania
endocrinopathy and, 526
Manic-depressive disorder, 151–57
Maltreatment
see Child abuse
Mechanical interdependence, 139
Melphalan
myeloma treatment and, 171–74
Mesenteric ischemia, 107
acute, 107–17
nonocclusive, 107–17
papaverine and, 107, 110–17
Metabolic bone disease, 17
Methylmalonate, 311, 316–20
cobalamin deficiency and, 311, 316–20
Mitogenesis, 567–79
Mixed cryoglobulinemia, 460
Monoclonal gammopathy of undetermined significance (MGUS), 167–68, 171
Mucormycosis, 482–83
Multidrug resistance
cancer treatment and, 277–85
Multiple sclerosis
HTLV-I virus and, 102
Myelodysplasia, 491, 493, 498–99
Myeloid metaplasia-myelofibrosis, 495, 497
Myeloma
multiple, 501
plasma cell, 167–75
Myeloproliferative disorders, 491, 495–99
Myocardial infarction, 1–4, 35–44, 133–35
cocaine abuse and, 133–35
stunned myocardium and, 1
thrombotic occlusion and, 42–43
Myocardial ischemia, 1–6, 225–40
acute, 225–40
adenine nucleotide pool and, 225–26, 230–32
hibernating myocardium and, 1, 5–6
reperfusion and, 226, 238–40
total, 228–35
Myocardial relaxation, 411, 418–32
calcium and, 418–32
Myocardial reperfusion, 1–5
stunned myocardium and, 1–5
Myocarditis
cocaine abuse and, 133, 135–36
Myocardium
angioplasty and, 5–6
calcium homeostasis and, 3
cardiopulmonary bypass and, 4
cell death in, 2
hibernating, 1–2, 5–6
coronary artery bypass surgery and, 5
pharmacologic agents for, 5
stunned, 1–5
oxygen free radicals and, 3
unstable angina and, 4

N

Neoplasia
clonal growth and, 491–502
Nephropathy
HIV-associated, 391–400
Nephrotic syndrome
HIV virus and, 391–400
Nonadrenergic noncholinergic inhibitory (NANCI) system, 142
airway hyperresponsiveness and, 142
Nonnucleoside reverse transcriptase inhibitors, 79–80
Nuclear cardiology, 119–25
Nursing homes, 267–75
tubercle bacilli in, 267–75
tuberculosis among elderly in, 267–75
Nutrition
blood pressure and, 347–53
Nutritional assessment, 549–63

O

Obesity, 205–14
autonomic nervous system and, 211
genetic, 212–14
endocrine system and, 211–12
ventromedial hypothalamus and, 212
Oncogenes, 167–75
chromosome abnormalities and, 169–70
Osteo-induction factors, 22
Osteopenia
thyroid hormone and, 341–45
Osteoporosis, 17, 341–45
thyroid hormone and, 341–45
Oxygen free radicals
myocardial stunning and, 3, 5

P

Papaverine, 107, 110–17
nonocclusive mesenteric ischemia and, 107, 110–17
Paranasal sinus infection, 471–88
immunocompromised hosts and, 486–88
Paraplegia
tropical spastic, 97–98, 101
Parasitic diseases
transfusion-associated, 303–4
Parathyroid hormone (PTH)
bone metabolism and, 18, 20–23
Parathyroid hormone, 342
Pentamadine
aerosolized, 287, 289–91
intramuscular, 292
intravenous, 292
Pentamide isethionate, 288
Percutaneous transluminal coronary angioplasty (PTCA)
coronary artery disease, 127
Pericardial constraint, 415–16
Periventricular white matter
affective disorders and, 261–64
P-glycoprotein, 277–80
Phosphorus
hypertension and, 352
Pituitary adenomata, 525

Plasma cell myeloma, 167–75
chromosome abnormalities and, 169–70
treatment of, 171–75
Platelet-derived growth factor, 567–79
Pneumocystis carinii pneumonitis, 287–93
prophylaxis, 291–93
treatment, 288–91
Polyarteritis nodosa, 460
Polycystic ovarian disease, 199–204, 374
androgens and, 199–204
diabetes and, 203
hyperinsulinemia and, 199–201
insulin resistance and, 203, 374
Polycythemia vera, 491, 497–98
Polymyositis, 97
Potassium
blood pressure and, 347, 349–50, 352
Prednisone
myeloma treatment and, 171–74
Primaquine, 287
Prostate cancer, 9–5
diagnosis of, 10–12
prostate-specific antigen and, 9–11, 13–15
radical prostatectomy and, 9
treatment of, 13–15
Prostate-specific antigen (PSA), 9–11, 13–15
Protease inhibitors, 80
Protein-sparing, 549, 554–55
glomerular macrophages and, 28–29
glomerulosclerosis and, 29
Protooncogenes, 381, 386–87
acute myeloid leukemia and, 386–87
Psychoneuroendocrinology, 520
Pulmonary embolism
see Chronic pulmonary embolism

R

Radical prostatectomy, 9, 13–15
Radionuclide angiography, 423
Reactivation, 61–62
Recombinant CD4, 78–79
Renal disease
end-stage, 391, 393–400
Renal disease
cell-mediated immunity in, 25–31
See also Glomerulonephritis, Glomerulosclerosis
Renal failure
acute, 391, 393
Renin-angiotensin-aldosterone system, 537
Reperfusion
ischemic myocardium and, 226, 238–40
Restenosis, 127–32
dialysis and, 131
factors influencing incidence of, 130–31
intimal hyperplasia and, 127–32
pathophysiologic mechanisms of, 128–30
prevention of, 131–30
Restriction fragment length polymorphism (RFLP) markers
linkage studies in schizophrenia and, 151, 155
Retinoic acid
leukemia treatment with, 385–87
Retroviral infections
non-AIDS, 97–103

S

Salmonella, 406
Schilling test for cobalamin absorption, 318–19
Schizophrenia, 151–57, 526–27
endocrinology and, 526–27
genetic epidemiology of, 154–55
linkage studies in, 155–56
log of odds (LOD) scores and, 155–56
Sepsis, 549–52
Skeletal tissue, 17–23
Sinusitis
paranasal, 471–88
immunocompromised hosts and, 486–88
Small inducible genes, 571–74
Sodium
hypertension and, 347–53
Spasm
cocaine abuse and, 133–35
Splanchnic vasoconstriction, 107–17
Starvation, 550
Sterility
anabolic hormones and, 449, 452
Steroids
see Androgens, Corticosteroids
Strength
androgenic hormones and, 449, 451–55
Stunning
myocardial ischemia and, 1–5, 225
Systemic lupus erythematosus, 460
Systemic vasculitis, 459–67

T

Tat inhibitors, 80
Thallium scintigraphy, 119–25
Thrombolysis, 1, 3–4
Thrombocythemia, 495, 498
Thrombosis
pulmonary artery, 515
venous, 508
Thrombus
restenosis and, 128–29
Thyroid peroxidase, 91–95
Thyroid-stimulating hormone, 92–93
Thyrotropin (TSH), 341–45
Thyrotopin-releasing hormone, 342–43
Transcription, 61, 63
Transforming growth factor beta family (TGFβ)
bone metabolism and, 21–22
Transfusion
AIDS and, 297
audit criteria for, 297–300
autologous, 297, 300–1, 307
disease risk from, 301–4
homologous, 297, 301
minimal exposure, 301
viral inactivation for blood components and, 297, 306
Transplantation
bone marrow, 189–95
cardiac, 437–46
rejection and, 439, 443
Transrectal ultrasonography, 9, 11–12
Trimethoprim-dapsone, 287–88, 292–93
Trimethoprim-sulfamethoxazole, 288–93
Trimetrexate, 287–88
Tropical spastic paraplegia, 97–98, 101–2
Tubercle bacilli, 267–75
Tuberculin skin test, 267–75
Tumor progression, 167–75
interferon and, 174–75

V

Valproic acid
  treatment for alcohol withdrawal syndrome and, 331
Varicella-Zoster virus, 61, 64, 247, 249–56
Vasculitis
  systemic, 459–67
Vasoactive intestinal peptide (VIP)
  airway hyperresponsiveness and, 142
Vasopressin
  affective disorders and, 524–25
Verapamil, 277–78, 282–85
Very-low-density lipoprotein
  coronary heart disease risk and, 358–65
Victims
  child abuse, 217–24
    see also Child abuse
Vinblastine, 277–80
Vincristine
  myeloma treatment and, 173

W

Wegener's granulomatosis, 459, 460
Wegener's vasculitis, 459–67
Working Group on Hypertension in Diabetes, 543–44
Wound repair, 567–79

Z

Zidovudine (AZT), 69–76, 82, 249, 399–400
  glucuronide of, 70–71
  human immunodeficiency virus and, 69–76, 82
  human immunodeficiency virus associated nephropathy and, 399–400
  resistance to, 75–76